IL17A and non-small cell lung carcinoma: To further confirm the source of IL-17, we found that both the positive percentage (7.54 ± 0.67% vs. 2.85 ± 0.33%) of CD3+IL-17+ cells were significantly higher in TILs of NSCLC specimens than those of paracancerous ones (p < 0.0001, Figure 1C), suggesting that CD3+ T cells was the main source of IL-17A.